AstraZeneca’s Acalabrutinib Study: Real-World Insights for CLL Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is currently conducting a study titled ‘Retention Rate of Acalabrutinib in a Non-interventional Setting.’ The primary aim of this research is to gather real-world data on the retention rates of Chronic Lymphocytic Leukemia (CLL) patients prescribed with acalabrutinib in Germany. This study is significant as it seeks to understand therapy adherence, treatment efficacy, and overall survival, while also analyzing psychological factors affecting patient perception and control over their health.

The intervention being tested is acalabrutinib, a medication used to treat CLL. This study will observe its retention rate, which refers to how long patients continue their prescribed therapy in a real-world setting, providing insights into its effectiveness and patient adherence.

This is an observational study with a cohort model and a prospective time perspective. It will include adult CLL patients newly prescribed with acalabrutinib, either as monotherapy or in combination with obinutuzumab, without restrictions on age, disease stage, or genetic risk factors.

The study began on December 12, 2022, and is currently recruiting participants. The last update was submitted on July 25, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.

The outcome of this study could influence AstraZeneca’s stock performance by providing valuable data on acalabrutinib’s real-world effectiveness. Positive results could enhance investor confidence and position AstraZeneca favorably against competitors in the oncology market.

The study is ongoing, and further details are available on the ClinicalTrials portal.